8月11日上榜的成交活跃股中，康方生物通过港股通渠道成交金额为11.00亿港元，净买入金额为3.06亿港元，不仅如此，该股已连续5日出现成交 净买入，累计净买入金额为11.82亿港元，其间股价上涨5.72%。（数据宝） 注：本文系新闻报道，不构成投资建议，股市有风险，投资需谨慎。 （原标题：康方生物获南向资金连续5天净买入） 康方生物获南向资金连续5天净买入，累计净买入金额为11.82亿港元，股价累计上涨5.72%。 证券时报•数据宝统计显示，8月11日港股通（包括沪市港股通及深市港股通）成交活跃股合计成交294.32亿港元，净卖出金额为10.21亿港元。 ...

证券时报·数据宝统计，8月11日港股通全天合计成交金额为1158.14亿港元，成交净买入0.38亿港元。 具 体来看，沪市港股通成交金额697.39亿港元，成交净卖出1.80亿港元；深市港股通成交金额460.75亿港 元，成交净买入2.19亿港元。 成交活跃股方面，沪市港股通前十大成交活跃股中，中芯国际成交额为32.68亿港元，成交金额居首； 其次是小米集团-W、腾讯控股，成交金额分别为19.50亿港元、19.35亿港元。以净买卖金额统计，小米 集团-W净买入额为3.70亿港元，净买入金额居首，该股收盘股价下跌0.88%。净卖出金额最多的是小鹏 汽车-W，净卖出3.96亿港元，收盘股价上涨5.36%。 8月11日恒生指数上涨0.19%，报收24906.81点，全天南向资金通过港股通渠道合计净买入0.38亿港元。 （文章来源：证券时报网） 8月11日港股通成交活跃股 | 代码 | 简称 | 类型 | 成交金额（万港元） | 成交净买入（万港元） | 日涨跌幅（%） | | --- | --- | --- | --- | --- | --- | | 00981 | 中芯国际 | 港股通(沪) | 326760.6 ...

Group 1 - Southbound funds net bought Hong Kong stocks worth 38.34 million HKD on August 11, with notable net purchases in Xiaomi Group (562 million HKD) and Kangfang Biotech (305 million HKD) [1] - Xiaomi has seen a continuous net buying trend for three days, totaling 2.75701 billion HKD, while Kangfang Biotech has experienced five consecutive days of net buying, amounting to 1.18185 billion HKD [1] Group 2 - Xiaomi Group's stock slightly declined by 0.88%, marking five consecutive trading days in the red, with a projected revenue of 117.97 billion CNY for Q2, reflecting a year-on-year growth of 32.71% [2] - Adjusted net profit for Xiaomi is expected to reach 10.18 billion CNY, a year-on-year increase of 64.84%, despite a loss of 360 million CNY from electric vehicles and innovation businesses [2] - The target price for Xiaomi has been lowered by 9% to 70 HKD, with projected P/E ratios of 34.4x and 25.1x for 2025 and 2026, respectively, indicating a potential upside of 29.6% [2] Group 3 - XPeng Motors' stock surged by 5.36% following the announcement that its first extended-range model, the XPeng X9, has entered the new vehicle public announcement list, indicating an upcoming launch [2] - XPeng's CEO confirmed that the XPeng X9, described as a "super electric vehicle," is set to officially launch in the fourth quarter [2] Group 4 - Innovent Biologics' stock fell by 1.42%, with Citic Securities projecting a strong recovery trend in the medical health industry by the second half of 2025, emphasizing the importance of innovation and internationalization [2] - The report suggests that the innovative drug sector will benefit from domestic policy support, leading to a potential upward trend in the sector [2]

据统计，南下资金已连续3日净买入小米，共计27.5701亿港元；连续5日净买入康方生物、共计11.8185 亿港元。(格隆汇) 格隆汇8月11日｜南下资金今日净买入港股3834.39万港元。其中： 净买入小米集团-W 5.62亿、康方生物3.05亿、东方甄选1.87亿、晶泰控股1.16亿； 净卖出小鹏汽车-W 6.64亿、信达生物5.27亿、腾讯控股3.39亿、美团-W 2.64亿、阿里巴巴-W 2.33亿、 中芯国际2.37亿。 | | D. Hos mill | | | | 下载 文川 | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | 流跌幅 | 净买入额(亿) | 成交额 | 名称 | 涨跌幅 | 净买入额(亿) | 成交额 | | 中心国际 | 0.1% | 0.47 | 32.68 Z | 中古国际 | 0.1% | -2.84 | 22.25 L | | 小米集团-W | -0.9% | 3.70 | 19.50亿 | 解讲控股 | 0.0% | -4.32 | 15.50 Z | | 腾讯控股 | 0.0% | 0.93 ...

Core Insights - Southbound capital transactions today amounted to approximately 115.814 billion HKD, marking a significant contraction and reaching a near 24-day low, accounting for 57.65% of the total turnover of the Hang Seng Index [2] - The Hang Seng Index experienced a slight increase of 0.19%, closing at 24,906.81 points, with a net inflow of southbound capital of about 38.35 million HKD [2] - Notable net purchases included Xiaomi Group-W (5.62 billion HKD), Kangfang Biotech (3.06 billion HKD), and Dongfang Zhenxuan (1.88 billion HKD) [2] - Significant net outflows were observed in XPeng Motors-W (6.65 billion HKD), Innovent Biologics (5.28 billion HKD), Tencent Holdings (3.40 billion HKD), Meituan-W (2.65 billion HKD), and Alibaba-W (2.34 billion HKD) [2] Company Performance - Xiaomi Group-W saw a decrease of 0.88%, with short-term capital continuing to flow in, accumulating 2.137 million shares over the past five days [3] - Kangfang Biotech increased by 0.25%, but short-term capital was primarily flowing out, with a reduction of 286,000 shares over the past five days [3] - Dongfang Zhenxuan rose by 3.32%, with short-term capital predominantly flowing in, adding 412,000 shares over the past five days [3] - XPeng Motors-W increased by 5.36%, with short-term capital also flowing in, accumulating 226,000 shares over the past five days [3] - Innovent Biologics decreased by 1.42%, with short-term capital flowing out, reducing 609,000 shares over the past five days [3] - Tencent Holdings remained unchanged, with short-term capital flowing in, adding 581,000 shares over the past five days [3] - Meituan-W decreased by 1.32%, with a slowdown in capital inflow, accumulating 1.167 million shares over the past five days [3] - Alibaba-W increased by 1.89%, with short-term capital flowing in, adding 1.642 million shares over the past five days [3]

Summary of Key Points Core Viewpoint - On August 11, southbound funds recorded a transaction volume of 115.814 billion HKD, with a net inflow of approximately 0.038 billion HKD, indicating mixed investor sentiment in the Hong Kong market [1]. Group 1: Major Net Buy and Sell Activities - Significant net buying was observed in Xiaomi Group-W (01810.HK) with 5.62 billion HKD, Kangfang Biotech (09926.HK) with 3.06 billion HKD, and Dongfang Zhenxuan (01797.HK) with 1.88 billion HKD [1]. - Major net selling was noted in XPeng Inc. (09868.HK) with 66.496 billion HKD, Innovent Biologics (01801.HK) with 52.789 billion HKD, and Tencent Holdings (00700.HK) with 33.983 billion HKD [1]. Group 2: Individual Stock Performance - Xiaomi Group-W experienced a decline of 0.88% with net buying of 3.70 billion HKD from the Shanghai-Hong Kong Stock Connect and 1.92 billion HKD from the Shenzhen-Hong Kong Stock Connect [1]. - Kangfang Biotech saw a slight increase of 0.25% with a net inflow of 3.06 billion HKD from the Shenzhen-Hong Kong Stock Connect [1]. - Dongfang Zhenxuan rose by 3.32%, with net buying of 2.01 billion HKD from the Shanghai-Hong Kong Stock Connect and a net sell of 131.974 million HKD from the Shenzhen-Hong Kong Stock Connect [1]. - Crystal Tech Holdings (02228.HK) increased by 4.78% with net buying of 1.17 billion HKD from the Shanghai-Hong Kong Stock Connect [2]. - CSPC Pharmaceutical Group (01093.HK) rose by 0.97% with a net inflow of 386.093 million HKD from the Shenzhen-Hong Kong Stock Connect [3]. - Hua Hong Semiconductor (01347.HK) fell by 3.68% with net buying of 360.177 million HKD from the Shanghai-Hong Kong Stock Connect [4]. - XPeng Inc. increased by 5.36% but faced significant net selling of 39.574 billion HKD from the Shanghai-Hong Kong Stock Connect and 26.922 billion HKD from the Shenzhen-Hong Kong Stock Connect [5]. - Innovent Biologics declined by 1.42% with net selling of 30.133 billion HKD from the Shanghai-Hong Kong Stock Connect and 22.656 billion HKD from the Shenzhen-Hong Kong Stock Connect [6]. - Tencent Holdings remained stable with no change in price, but had net buying of 925.043 million HKD from the Shanghai-Hong Kong Stock Connect and net selling of 43.233 billion HKD from the Shenzhen-Hong Kong Stock Connect [6]. - Meituan-W (03690.HK) decreased by 1.32% with net selling of 37.107 billion HKD from the Shanghai-Hong Kong Stock Connect and net buying of 1.06 billion HKD from the Shenzhen-Hong Kong Stock Connect [6].

【华福证券：维持康方生物买入评级】智通财经8月11日电，华福证券就康方生物(09926.HK)发布研报 称，该公司自研双抗AK112进度全球领先，有望占据全球二代IO市场的最大份额。预计公司2025-2027 年营业收入分别为35.18/57.65/93.72亿元，归母净利润分别为-1.86/8.03/29.66亿元，合理市值为2228亿港 元，维持买入评级。 转自：智通财经 ...

Core Insights - The top three companies by Hong Kong Stock Connect holding ratios are China Telecom (00728) at 74.70%, Green Power Environmental (01330) at 70.03%, and China Shenhua (01088) at 68.18% [1] - Tencent Holdings (00700), Alibaba-W (09988), and Kuaishou-W (01024) saw the largest increases in holding amounts over the last five trading days, with increases of +2.39 billion, +2.11 billion, and +1.60 billion respectively [1] - The largest decreases in holding amounts over the last five trading days were recorded by the Tracker Fund of Hong Kong (02800) at -7.82 billion, Hang Seng China Enterprises (02828) at -4.88 billion, and China Mobile (00941) at -1.34 billion [1] Hong Kong Stock Connect Latest Holding Ratios - China Telecom (00728): 10.368 billion shares, 74.70% holding ratio [1] - Green Power Environmental (01330): 0.283 billion shares, 70.03% holding ratio [1] - China Shenhua (01088): 2.303 billion shares, 68.18% holding ratio [1] - Other notable companies include Tianjin Chuangye Environmental (01065) at 64.43% and New天绿色能源 (00956) at 63.76% [1] Recent Increases in Holdings (Last 5 Trading Days) - Tencent Holdings (00700): +2.39 billion, +4.2595 million shares [1] - Alibaba-W (09988): +2.11 billion, +18.1194 million shares [1] - Kuaishou-W (01024): +1.60 billion, +20.1638 million shares [1] - Other companies with significant increases include China Shenhua (01088) and China Life (02628) [1] Recent Decreases in Holdings (Last 5 Trading Days) - Tracker Fund of Hong Kong (02800): -7.82 billion, -30.82404 million shares [1] - Hang Seng China Enterprises (02828): -4.88 billion, -5.35312 million shares [1] - China Mobile (00941): -1.34 billion, -1.54265 million shares [1] - Other companies with notable decreases include Southbound Hang Seng Technology (03033) and Guotai Junan International (01788) [1]

Core Viewpoint - The investment value of innovative drugs is not a short-term pulse but a long-term industrial dividend, with optimal solutions for sharing this dividend through index tools in golden tracks [1] Group 1: Performance of Innovative Drug Indices - Since July, the National Index for Hong Kong Stock Connect Innovative Drugs and the China Securities Innovative Drug Industry Index have reached new highs, with year-to-date increases of 106.7% and 32.3% respectively as of July 31 [2] - The impressive performance of these indices reflects a decade-long transformation of China's innovative drug industry from "follower" to "leader" [2] - Recent inflows into ETFs tracking innovative drug indices have been significant, with a net inflow of 4.26 billion yuan from August 4 to August 8 and over 16 billion yuan since June [2] Group 2: Index Adjustments and Sensitivity - The recent upgrade of the Hong Kong Stock Innovative Drug Index aims to enhance its focus by excluding CXO companies and increasing adjustment frequency from semi-annual to quarterly, effective August 12 [3][4] - This adjustment allows the index to better capture the core drivers of the innovative drug industry, focusing on pharmaceutical companies that lead drug development and hold key patents [3] - The increased adjustment frequency enhances the index's sensitivity, enabling it to quickly identify emerging growth companies in a rapidly evolving market [4] Group 3: Policy Support for Innovative Drugs - The innovative drug industry has received significant policy support this year, with the State Council's 2025 strategic goal to create a globally competitive innovation ecosystem [5] - Multiple regulatory bodies have introduced supportive measures, including optimizing review processes and reopening IPO channels for unprofitable companies [6] - The 2024 medical insurance fund expenditure on innovative drugs is projected to be 3.9 times that of 2020, with an annual growth rate of 40% [7] Group 4: Market Dynamics and Future Outlook - By the end of 2024, China is expected to have 3,575 original innovative drugs in clinical trials, surpassing the U.S. and becoming the global leader [7] - The proportion of first-in-class (FIC) drugs has increased from less than 10% in 2015 to 24% in 2024, indicating a significant enhancement in original innovation capabilities [7] - The innovative drug market in China currently accounts for less than 10% of the total pharmaceutical market, indicating substantial growth potential compared to over 20% in other G20 countries [9] Group 5: Investment Opportunities in Innovative Drugs - The China Securities Innovative Drug Industry Index has shown a year-to-date increase of 32.3%, with significant upside potential remaining [8] - The long-term growth of the innovative drug market is supported by an aging population and increasing demand for treatments for chronic diseases and rare diseases [8] - Investing in ETFs that track the innovative drug sector provides a way to mitigate risks associated with individual stock investments while capitalizing on overall industry growth [9]

Core Insights - The company AK112 is leading globally in the development of second-generation immune-oncology (IO) therapies and is expected to capture the largest market share in this segment [1][2] - The broad-spectrum anti-cancer effects of PD-1 and VEGF targets are promising, with a significant existing market potential of nearly $60 billion, driven by the synergistic mechanisms of dual-target therapies [1] - The company has made substantial progress in clinical trials, with multiple Phase III studies underway and a unique position as the only approved PD-1/VEGF dual antibody globally [2] Market Potential - The global peak sales for VEGF monoclonal antibody Bevacizumab reached approximately $7.1 billion in 2019, while combined global sales for PD-1/PD-L1 monoclonal antibodies are projected to reach $51.6 billion by 2024 [1] - The total upfront payments for PD-1/VEGF or PD-L1/VEGF dual antibody licensing agreements have reached $3.9 billion, with total deal values amounting to $28.8 billion [1] Clinical Development - AK112 has received approval for two indications in China, with one included in the national medical insurance directory, showcasing its leading global progress [2] - The company is advancing multiple Phase III clinical studies for various cancers, including NSCLC, triple-negative breast cancer, and pancreatic cancer, which could potentially replace existing market products [2] - The first international registration trial for the PD-1/CTLA-4 dual-specific antibody, AK104, has been approved, indicating significant clinical and commercial potential [2] Financial Projections - Revenue forecasts for the company are estimated at 3.518 billion, 5.765 billion, and 9.372 billion yuan for 2025-2027, with net profits projected to be -186 million, 803 million, and 2.966 billion yuan respectively [3] - Assuming successful international Phase III trials for AK112, the risk-adjusted peak sales are estimated at approximately $19.7 billion [3] - Based on a DCF valuation with a WACC of 8.06% and a perpetual growth rate of 1%, the reasonable market capitalization is calculated to be 222.8 billion HKD [3]